{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:05:43Z","timestamp":1789592743552,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001588","name":"Enterprise Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.kint.2024.11.025","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T04:06:26Z","timestamp":1739937986000},"page":"394-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Can we crystallize the role of urate-lowering treatment in chronic kidney disease?"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-5382","authenticated-orcid":false,"given":"Austin G.","family":"Stack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.11.025_bib1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.11.025_bib2","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.11.025_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1681\/ASN.0000000000000326","article-title":"Combination treatment with verinurad and allopurinol in CKD: a randomized placebo and active controlled trial","volume":"35","author":"Heerspink","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.11.025_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187550","article-title":"Effects of uric acid-lowering therapy in patients with chronic kidney disease: a meta-analysis","volume":"12","author":"Su","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2024.11.025_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41581-019-0174-z","article-title":"The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD","volume":"15","author":"Sato","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2024.11.025_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.kint.2024.11.025_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.kint.2024.10.022","article-title":"Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy","volume":"107","author":"Ghang","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.11.025_bib8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.11.025_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031550","article-title":"Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study","volume":"9","author":"Stack","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.kint.2024.11.025_bib10","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1681\/ASN.2020040523","article-title":"Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease","volume":"31","author":"Sellmayr","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824008627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824008627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:41:51Z","timestamp":1762231311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824008627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0085253824008627"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.11.025","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we crystallize the role of urate-lowering treatment in chronic kidney disease?","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.10.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}